Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals is dedicated to advancing therapies targeting rare neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenic Syndromes (CMS), MuSK-Myasthenia Gravis, and Spinal Muscular Atrophy. Catalyst is an integrated pharmaceutical company with the ability to develop and market new products, including recently approved Firdapse.

  • Date:Monday, February 11
  • Time:11:15 AM - 11:30 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23288
  • Goal for Presentation: Product Development and commercialization plans will be presented
  • Company Website:www.catalystpharma.com
  • Company HQ City:Coral Gables
  • Company HQ State:Florida
  • Company HQ Country:United States
  • Market Cap: $240 million
  • Ticker:CPRX
  • Exchange:Nasdaq
  • CEO/Top Company Official:Patrick McEnany
  • Year Founded:2002
  • Main Therapeutic Focus:Orphan/Rare Diseases
  • Lead Product in Development:Firdapse
  • Development Phase of Primary Product:Multiple Products in Market
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
Speakers
Steven Miller
Catalyst Pharmaceuticals, Inc.
Patrick McEnany
Catalyst Pharma
Back